Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Progression-Free Survival (PFS) | REVLIMID® (lenalidomide) + rituximab
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
A) Overall survival (OS) and (B) progression-free survival (PFS).... | Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
Progression Free Survival Curve. Median PFS 4.5 months 95% CI 3.5–5.3.... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
